Vor Bio presents ‘positive’ data update on trem-cel

Vor Bio presented updated clinical data from patients treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel in patients with acute myeloid leukemia, AML. “With this additional hematologic protection data in multiple patients over multiple doses of Mylotarg, we are now seeing the promise of our approach come to light as a potential next-generation therapeutic option for AML patients,” said Eyal Attar, MD, Vor Bio’s Chief Medical Officer. “Now with VCAR33ALLO in the clinic, we have the potential for an even better combination with trem-cel with the goal of providing durable responses or even a potential cure for AML.” “The results being presented further validate Vor Bio’s platform and approach. We are excited to see that trem-cel has worked as expected in these patients, providing them with hematologic protection and exposing their leukemia to targeted therapy,” said Dr. Guenther Koehne.